Targeting IL-6 Signaling: Safety and Effectiveness in Older Patients with Rheumatoid Arthritis

Area of Science:

• Immunology and Rheumatology
• Pharmacovigilance and Drug Safety
• Geriatric Medicine

Background:

• Interleukin-6 (IL-6) is a key mediator of inflammation in immune-mediated inflammatory diseases (IMIDs).
• IL-6 receptor (IL-6R) inhibitors are effective treatments for rheumatoid arthritis (RA).
• Older age is a risk factor for adverse events, necessitating safety evaluations of IL-6R inhibitors in elderly RA patients.

Purpose of the Study:

• To evaluate the safety and effectiveness of IL-6R inhibitors in older patients with RA.
• To analyze postmarketing surveillance (PMS) and registry data for sarilumab (SAR) and tocilizumab (TCZ) in elderly RA populations.

Main Methods:

• Analysis of postmarketing surveillance data for sarilumab in Japanese RA patients.
• Review of PMS data from Japan and registry data from France and Germany for tocilizumab.
• Comparative assessment of safety and effectiveness across different age groups.

Main Results:

• Anti-IL-6R therapies demonstrated good tolerability in older RA patients.
• No increased risk of cardiovascular events or malignancies was observed with IL-6R inhibitors in this population.
• Tocilizumab showed slightly reduced effectiveness in older patients, while sarilumab maintained similar effectiveness across age groups.

Conclusions:

• IL-6R inhibitors are generally safe and effective for older patients with RA.
• These therapies are suitable for the growing elderly population with IMIDs.
• The use of anti-IL-6R antibodies is expected to expand to other IMIDs globally, especially in aging societies.